When an infection-specific antigen is combined with the blood, rapid re-stimulation of antigen-specific T-cells occurs, leading to the secretion of interferon-gamma (IFN-γ), which can be measured as a marker of an immune response. CMV immune response monitoring enables healthcare providers to pinpoint patients with higher risks of developing complications, thereby allowing them to administer suitable treatments and mitigate the chances of full-blown CMV disease and transplant loss. As a result, the TSN advises QuantiFERON-CMV to be used for nationwide immune response monitoring the year after surgery. Patients testing positive with an adequate immune response to the virus should be released from prophylactic treatment after three months, while those testing negative, and more at risk to CMV disease, should be monitored for up to six months.
- Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights.
- More compact kits and new ways of packing them reduce the amount of cardboard needed for packaging.
- The independent rating agency has elevated QIAGEN’s rating from C+ to B-, reaffirming its “Prime” status and placing it among the top 10% of all companies in the “Health Care Equipment & Supplies” industry.
- Qiagen generates over 85% of its revenue from consumables with the balance coming from instrumentation and related services.
The software will be used at testing sites throughout Denmark and support the nationwide initiative to offer sequencing-based solutions for cancer patients. The report showcases QIAGEN’s strategic approach towards sustainable transformation, including its ambitious emissions reduction goals, diversity and inclusion initiatives, and efforts to expand global access to vital medical testing. QIAGEN recently completed the full acquisition of Verogen for $150 million in cash paid from existing reserves.
Our automation systems bring together all of these steps in seamless end-to-end workflows. Offers molecular diagnostics, applied testing, academic and pharmaceutical research. It also offers secondary sample technology consumable (kits and components for purification of nucleic acids, instruments for nucleic acid purification, and accessories). Qiagen N.V was founded in 1986 and is headquartered in Venlo, the Netherlands.
QIAGEN strives to ensure that its suppliers and customers share the same values and continues to promote responsible and ethical business conduct combined with respect for human rights as a fundamental value. Qiagen NV raised its outlook for 2020 and 2021 on Tuesday after increasing production amid the coronavirus pandemic. The Germany-based provider of sample and assay technologies now expects net sales to grow by at least 32%… QIAwave kits use up to 62% less plastic and up to 58% less cardboard than QIAGEN’s most popular kits for extracting DNA, RNA and plasmid DNA from samples, making them a more sustainable choice for laboratories. The QIAwave product line is the first to use both recycled plastics and space-saving chemical concentrates.
- Verogen is a dedicated developer of DNA-based biometric human identification products for analysis of forensic genomic samples.
- This tailored approach not only enhances patient outcomes, but also contributes to cost savings within the healthcare system.
- The products feature fewer components, waste tubes made from 100% recycled plastic, and suitable buffer concentrates in smaller bottles.
- From doctors seeking solutions to diagnose and prevent disease, to researchers conquering new scientific frontiers and translating genomic insights into new medicines, we are inspired by their discoveries and breakthroughs.
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights.
QGEN vs Diagnostic & Research Stocks
Additionally, it’s recommended for patients undergoing hemodialysis and those about to start immunomodulatory treatment due to renal insufficiency. The World Health Organization (WHO) also strongly recommends TB infection screening for all immunocompromised patients including those receiving organ or hematological transplants and those on dialysis. QuantiFERON-TB Gold Plus requires only one patient visit and is much more accurate for diagnosing latent TB in populations that are at the highest risk for infection than the century-old, two-visit Tuberculin skin test (TST).
Qiagen NV premium industry data and analytics
The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical and biotechnology and life sciences research markets. The company offers products directly and also through a network of independent distributors.
For example, more than 16 million QuantiFERON-TB tuberculosis tests were performed globally, with significant contributions to high-burden, low-resource countries such as Uganda, Democratic Republic of the Congo, Kenya, Malawi, Indonesia, India, and Brazil. Our desire to innovate is driven by our customers passion in their fields. From doctors seeking solutions to diagnose and prevent disease, to researchers conquering new scientific frontiers and translating how to start forex trading genomic insights into new medicines, we are inspired by their discoveries and breakthroughs. Improve competitive bidding with insights into all publicly disclosed IT services contracts for Qiagen NV (including IT outsourcing, business process outsourcing, systems integration & consulting and more). Here you will find stock quotes and a chart showing the up and down trends of QIAGEN NV QGEN stock, and you can buy stock in the app at the current price.
Bio-Rad and German-based biotech Qiagen weighing latest tie-up in medical-diagnostic market
With an incidence rate ranging from 8% to 32%1, CMV disease stands as the most prevalent infectious complication following kidney transplant procedures. The required immunosuppressive medications, essential for preventing organ rejection, weaken the patient’s immune system, making it more challenging to control viral infections. Post-transplant CMV poses the risk of causing severe complications such as direct harm to the transplanted organ, graft rejection or dysfunction, and heightened susceptibility to other infections. QIAGEN is aiming to reduce its plastic footprint, in particular by replacing expanded polystyrene (EPS) boxes for cooled shipments with recyclable alternatives made of straw and other forms of plastic packaging with more eco-friendly alternatives.
QIAGEN has been recognized by various rating agencies for its sustainability efforts, including a “Prime” status by ISS ESG and an A rating from MSCI ESG Research. Since early 2020, QIAGEN worked closely with governments, public health authorities, and customers worldwide to ensure the availability of critical COVID-19 testing diagnostics, covering the needs of clinical and research customers. The tests NADEX and kits cover manual to automated sample processing, low to high throughput, single-plex to multi-plex, and from active infection testing to detecting previous viral exposure. QIAGEN’s QuantiFERON Technology is a unique in vitro diagnostic method for detecting cell-mediated immune responses from whole blood samples. It works by identifying specific T-cells in individuals with infectious agent exposure.
QIAGEN and Verogen have been commercialization partners since announcing a distribution agreement in June 2021. Japan to become the latest of more than 100 countries where QIAstat-Dx is available for molecular testing in diagnosing over 20 respiratory diseases from one patient sample // Generates actionable res… TUNIS, Tunisia, Sept. 28, 2023 (GLOBE NEWSWIRE) — QIAGEN today announced that the comprehensive QuantiFERON immune response blood tests have been recommended for use by clinicians in Tunisia to help …
By the end of 2022, the top 95% of suppliers by expenditure had signed the policy, and all suppliers that accept purchase orders from 2023 need to agree to comply with the policy. In 2022, 95% of QIAGEN’s overall purchasing volume came from OECD countries. Analytical instruments company Thermo Fisher Scientific Inc. reported Wednesday first-quarter profit and revenue that topped expectations, as revenue beats in its laboratory products, specialty diagnostics and life scienc… In 2018, QIAGEN transferred its listing to New York Stock Exchange. In April 2018, QIAGEN acquired the Spanish firm STAT-Dx and launched the QIAstat-Dx molecular diagnostics platform. Verogen, a privately held company founded in 2017 and based in San Diego, supports the global human identification community with NGS tools and professional services to help resolve criminal and missing-persons cases.
Initiatives to reduce plastic include eco-friendly transport boxes in the EMEA region and replacing expandable polystyrene (EPS) coolers with environmentally friendly packaging at an initial US site. Verogen is a dedicated developer of DNA-based biometric human identification products for analysis of forensic genomic samples. Working closely with the forensic community, Verogen places exceptional value on flexible, scalable solutions that deliver reliable results. Verogen’s sequencing and analysis solutions are designed for use on the MiSeq FGx® Sequencing System from Illumina, Inc. With this acquisition, QIAGEN gains exclusive distribution rights for this version of the MiSeq sequencer designed specifically for forensics applications.
We publish analysis and forecasts to help you choose the right strategies for trading Qiagen N.V. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the Meet the Frugalwoods previous 50 trading days. The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit.